Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatri...
ESMO: AlphaMedix phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroend...
CHMP rejects Sanofi's Rezurock for chronic GVHD in the EU, while approving Wayrilz for ITP, highlighting mixed outcomes for...
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic neuroen...
AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful be...
